Fintel reports that on September 24, 2024, Baird downgraded their outlook for McKesson (NYSE:MCK) from Outperform to Neutral.

Robert W. Baird analyst Eric Coldwell downgraded the rating on McKesson (MCK – Research Report) to a Hold today, setting a price target ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Today, Benzinga's options scanner identified 12 options transactions for McKesson. This is an unusual occurrence. The ...

McKesson boasts solid revenue and EPS growth, supported by AI integration. Click here to read what offers a compelling ...

McKesson, a drug distributor and medical-products company, will own a 70% stake in the company. Back To Top ...

The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has gained 0.9% over this period. Now the key question is: Where could the stock be headed in the near term? While media ...

McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings ...

McKesson, a drug distributor and medical-products company, will own a 70% stake in the company. Core Ventures was set up by Florida Cancer Specialists & Research Institute, LLC, a physician-owned ...